NCT06079723Not yet recruiting
A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
Analyzing the Patterns of Patient Engagement and Trends in Participation Observed in Medullary Thyroid Cancer Clinical Trials
Source: ClinicalTrials.gov · Last updated 12 Oct 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Clinical studies, with a distinct emphasis on medullary thyroid cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications surpass conventional therapies, providing substantial evidence to endorse their broader adoption. The primary objective is to meticulously examine trial completion rates and voluntary withdrawals within this specific patient group. By actively participating in this observational study plays a critical role in pushing medical knowledge forward and advancing care for individuals suffering from the medullary thyroid cancer.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 6 Oct 2023
- Start date
- Nov 2024
- Primary completion date
- Nov 2025
- Lead sponsor
- Power Life Sciences Inc.
- Diseases
- Thyroid cancer
- NCT number
- NCT06079723
What you commit to
- Study type: Observational
- Planned participants: 500
- From Nov 2024 to the primary completion date, Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are currently receiving any other investigational drug.
Other illness
- Any serious and/or unstable pre-existing medical disorders
Other
- Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study
Who the study is looking for
- Confirmed diagnosis of medullary thyroid cancer
- Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
- No serious medical or psychiatric illness likely to interfere with participation in this clinical study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Power Life Sciences Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.